Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
Major Depressive Disorder
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depression, Omega-3, Boston
Eligibility Criteria
Inclusion Criteria: Men or women aged 18-80 years old. Must meet criteria for current Major Depressive Disorder. Exclusion Criteria: Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease History of seizure disorder. Substance use disorders, including alcohol, active within the last six months (past history is OK). History of multiple adverse drug reactions or allergy to the study drugs.
Sites / Locations
- Depression Clinical Research Program, Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
EPA
DHA
Placebo
Eicosapentaenoic acid (EPA) Omega-3, 1g/day
Docosahexaenoic acid (DHA) Omega-3, 1g/day
Placebo capsule (980mg soybean oil)